Startup crafts e-cigarette-inspired medical device; Biosensors eyes U.S. stent trial;

@FierceMedDev: BioFire Diagnostics wins FDA clearance for innovative GI panel. Article | Follow @FierceMedDev

@VarunSaxena2: Apple on medical tech hiring spree, a possible hint of iWatch plans. Story via Reuters | Follow @VarunSaxena2

@EmilyWFierce: New Dx machine from student at MIT uses magnets and lasers to quickly spot. More from the Boston Globe | Follow @EmilyWFierce

@MichaelGFierce: Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. Story via FierceDrugDelivery | Follow @MichaelGFierce

> Amid the boom in e-cigarettes, a startup is working on a medical device designed to help smokers quit. Article

> Hemostatic outfit Z-Medica has signed a deal with Taureon to get its hands on Novacol, an anti-bleeding device. News

> Biosensors won the FDA's blessing to start a U.S. clinical trial of its BioFreedom drug-coated stent. Item

Biotech News

@FierceBiotech: Bristol-Myers' armed antibody partner Ambrx shoots for an $86M IPO. Story | Follow @FierceBiotech

@JohnCFierce: Pfizer down more than 2% on some miserable Q1 numbers. Only more fuel for the M&A fire. | Follow @JohnCFierce

@DamianFierce: It's FDA decision day for epanova, the cardio drug AstraZeneca picked up in its $443M deal for Omthera. | Follow @DamianFierce

@EmilyMFierce: As MERS arrives in U.S., Novavax, UofMaryland report positive preclinical results for MERS vaccine. Story via FierceBiotech Research | Follow @EmilyMFierce

> Global R&D centers brace for another blow as Pfizer circles AstraZeneca. More

> Novartis' long-acting Signifor passes PhIII test for acromegaly. Story

> Regeneron jumps into next-gen gene therapy tech with $640M eye drug deal. Article

Pharma News

@FiercePharma: Pfizer's 'weak' Q1 numbers bolster case for AZ buy--and post-merger split, too. More | Follow @FiercePharma

@TracyStaton: Forest founder, CEO set for $100M-plus yield from Actavis buyout. Article | Follow @TracyStaton

@EricPFierce: With all of the deals going on, Teva CEO thinks a buy in biosimilars might be a move it would make. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Positive H7N9 data could help Novartis hawk flu vax business. Article | Follow @CarlyHFierce

> Big Pharma aims to cast off old drugs to raise $42B for higher-profit R&D efforts. News

> Merck proposal to sell Singulair without a prescription hits resistance. Story

> Up, up, up: After Allergan offer, would-be buyer Ackman reaps $1.2B in gains. More

CRO News

> Covance slips after narrowing its 2014 ambitions. Article

> Charles River ticks up revenue M&A on tap. More

> Quintiles keeps rolling with another $1B quarter. Report

> Parexel boosts revenue with eyes on a $1.9B year. Article

> Icon cranks up its 2014 expectations after another leap. Story

Biotech IT News

> Bina, SAS and others pitch new tools to boost biopharma R&D. Article

> Novartis steps up MS digital presence with iPhone app. Item

> Buzz: Google Ventures leading $100M round in oncology Big Data platform. More

> Canada to set up cancer cloud computing facility. News

> Medidata unveils Sanofi deal as it looks to recover from rocky April. Story

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.